Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of a Novel Lipid Metabolism-related Gene Prognostic Signature for Patients with Colorectal Cancer

Author(s): Jing Zhan, Wei Cen, Junchang Zhu and Yunliang Ye*

Volume 19, Issue 2, 2024

Published on: 31 July, 2023

Page: [209 - 222] Pages: 14

DOI: 10.2174/1574892818666230731121815

Price: $65

Abstract

Background: The purpose of this study was to explore the expression profiles of lipid metabolism-related genes in patients with Colorectal Cancer (CRC).

Methods: The lipid metabolism statuses of CRC patients from The Cancer Genome Atlas (TCGA) were analyzed. Risk characteristics were constructed by univariate Cox regression and minimum Absolute contraction and Selection Operator (LASSO) Cox regression. A histogram was constructed based on factors such as age, sex, TNM stage, T stage, N stage, and risk score to provide a visual tool for clinicians to predict the probability of 1-year, 3-year, and 5-year OS for CRC patients. By determining Area Under Curve (AUC) values, the time-dependent Receiver Operating characteristic Curve (ROC) was used to evaluate the efficiency of our model in predicting prognosis.

Results: A novel risk signal based on lipid metabolism-related genes was constructed to predict the survival of CRC patients. Risk characteristics were shown to be an independent prognostic factor in CRC patients (p <0.001). There were significant differences in the abundance and immune characteristics of tumor-filtering immune cells between high-risk and low-risk groups. The nomogram had a high potential for clinical application and the ROC AUC value was 0.827. Moreover, ROC analysis demonstrated that the nomogram model was more accurate to predict the survival of CRC patients than age, gender, stage and risk score.

Conclusion: In this study, we demonstrated a lipid metabolism-related genes prognosis biomarker associated with the tumor immune micro-environment in patients with CRC.

« Previous Next »
[1]
Keum N, Giovannucci E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019; 16(12): 713-32.
[http://dx.doi.org/10.1038/s41575-019-0189-8] [PMID: 31455888]
[2]
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394(10207): 1467-80.
[http://dx.doi.org/10.1016/S0140-6736(19)32319-0] [PMID: 31631858]
[3]
Provenzale D, Ness RM, Llor X, et al. NCCN guidelines insights: Colorectal cancer screening, version 2.2020. J Natl Compr Canc Netw 2020; 18(10): 1312-20.
[http://dx.doi.org/10.6004/jnccn.2020.0048] [PMID: 33022639]
[4]
Thomas M, Sakoda LC, Hoffmeister M, et al. Genome-wide modeling of polygenic risk score in colorectal cancer risk. Am J Hum Genet 2020; 107(3): 432-44.
[http://dx.doi.org/10.1016/j.ajhg.2020.07.006] [PMID: 32758450]
[5]
Weiser MR. AJCC 8th Edition: Colorectal cancer. Ann Surg Oncol 2018; 25(6): 1454-5.
[6]
Mohd Y, Balasubramanian B, Meyyazhagan A, et al. Extricating the association between the prognostic factors of colorectal cancer. J Gastrointest Cancer 2021; 52(3): 1022-8.
[http://dx.doi.org/10.1007/s12029-020-00535-4] [PMID: 33047269]
[7]
Cristea S, Coles GL, Hornburg D, et al. The MEK5–ERK5 kinase axis controls lipid metabolism in small-cell lung cancer. Cancer Res 2020; 80(6): 1293-303.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-1027] [PMID: 31969375]
[8]
Karasinska JM, Topham JT, Kalloger SE, et al. Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clin Cancer Res 2020; 26(1): 135-46.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1543] [PMID: 31481506]
[9]
Shen C, Xuan B, Yan T, et al. m6A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer 2020; 19(1): 72.
[http://dx.doi.org/10.1186/s12943-020-01190-w] [PMID: 32245489]
[10]
Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu Nada M, Elkord E. Immune checkpoints in circulating and tumor-infiltrating CD4+ T cell subsets in colorectal cancer patients. Front Immunol 2019; 10: 2936.
[http://dx.doi.org/10.3389/fimmu.2019.02936] [PMID: 31921188]
[11]
Zadka Ł, Chabowski M, Grybowski D, Piotrowska A, Dzięgiel P. Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer. Cancer Immunol Immunother 2021; 70(9): 2681-700.
[http://dx.doi.org/10.1007/s00262-021-02863-1] [PMID: 33625532]
[12]
Penny SA, Abelin JG, Malaker SA, et al. Tumor infiltrating lymphocytes target HLA-I phosphopeptides derived from cancer signaling in colorectal cancer. Front Immunol 2021; 12: 723566.
[http://dx.doi.org/10.3389/fimmu.2021.723566] [PMID: 34504498]
[13]
Ye L, Zhang T, Kang Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol 2019; 10: 2368.
[http://dx.doi.org/10.3389/fimmu.2019.02368] [PMID: 31681276]
[14]
Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 2017; 16(1): 41.
[http://dx.doi.org/10.1186/s12943-017-0600-4] [PMID: 28209166]
[15]
Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun 2021; 12(1): 2540.
[http://dx.doi.org/10.1038/s41467-021-22801-0] [PMID: 33953163]
[16]
Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab 2019; 30(3): 434-46.
[http://dx.doi.org/10.1016/j.cmet.2019.08.013] [PMID: 31484055]
[17]
Yu TJ, Ma D, Liu YY, et al. Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers. Mol Ther 2021; 29(7): 2350-65.
[http://dx.doi.org/10.1016/j.ymthe.2021.03.003] [PMID: 33677091]
[18]
Zhu Y, Gu L, Lin X, et al. Dynamic regulation of ME1 phosphorylation and acetylation affects lipid metabolism and colorectal tumorigenesis. Mol Cell 2020; 77(1): 138-149.e5.
[http://dx.doi.org/10.1016/j.molcel.2019.10.015] [PMID: 31735643]
[19]
Yang C, Huang S, Cao F, Zheng Y. A lipid metabolism-related genes prognosis biomarker associated with the tumor immune microenvironment in colorectal carcinoma. BMC Cancer 2021; 21(1): 1182.
[http://dx.doi.org/10.1186/s12885-021-08902-5] [PMID: 34740325]
[20]
Iwamoto H, Abe M, Yang Y, et al. Cancer lipid metabolism confers antiangiogenic drug resistance. Cell Metab 2018; 28(1): 104-117.e5.
[http://dx.doi.org/10.1016/j.cmet.2018.05.005] [PMID: 29861385]
[21]
Wu F, Zhao Z, Chai RC, et al. Prognostic power of a lipid metabolism gene panel for diffuse gliomas. J Cell Mol Med 2019; 23(11): 7741-8.
[http://dx.doi.org/10.1111/jcmm.14647] [PMID: 31475440]
[22]
Ma B, Jiang H, Wen D, et al. Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer. J Clin Endocrinol Metab 2019; 104(9): 3713-25.
[http://dx.doi.org/10.1210/jc.2018-02686] [PMID: 30942873]
[23]
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102(43): 15545-50.
[http://dx.doi.org/10.1073/pnas.0506580102] [PMID: 16199517]
[24]
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12(5): 453-7.
[http://dx.doi.org/10.1038/nmeth.3337] [PMID: 25822800]
[25]
Batista-Gonzalez A, Vidal R, Criollo A, Carreño LJ. New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages. Front Immunol 2020; 10: 2993.
[http://dx.doi.org/10.3389/fimmu.2019.02993] [PMID: 31998297]
[26]
Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B 2022; 12(2): 558-80.
[http://dx.doi.org/10.1016/j.apsb.2021.09.019] [PMID: 35256934]
[27]
Ko CW, Qu J, Black DD, Tso P. Regulation of intestinal lipid metabolism: Current concepts and relevance to disease. Nat Rev Gastroenterol Hepatol 2020; 17(3): 169-83.
[http://dx.doi.org/10.1038/s41575-019-0250-7] [PMID: 32015520]
[28]
Aguilar E, Esteves P, Sancerni T, et al. UCP2 deficiency increases colon tumorigenesis by promoting lipid synthesis and depleting NADPH for antioxidant defenses. Cell Rep 2019; 28(9): 2306-2316.e5.
[http://dx.doi.org/10.1016/j.celrep.2019.07.097] [PMID: 31461648]
[29]
Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology 2020; 158(2): 418-32.
[http://dx.doi.org/10.1053/j.gastro.2019.06.043] [PMID: 31394083]
[30]
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14(10): 1014-22.
[http://dx.doi.org/10.1038/ni.2703] [PMID: 24048123]
[31]
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13(4): 227-42.
[http://dx.doi.org/10.1038/nri3405] [PMID: 23470321]
[32]
Morgan MR, Byron A, Humphries MJ, Bass MD. Giving off mixed signals-Distinct functions of α 5 β 1 and α v β 3 integrins in regulating cell behaviour. IUBMB Life 2009; 61(7): 731-8.
[http://dx.doi.org/10.1002/iub.200] [PMID: 19514020]
[33]
Marelli UK, Rechenmacher F, Sobahi TRA, Mas-Moruno C, Kessler H. Tumor targeting via integrin ligands. Front Oncol 2013; 3: 222.
[http://dx.doi.org/10.3389/fonc.2013.00222] [PMID: 24010121]
[34]
Huang G, Ma J, Zhang L. Integrin subunit alpha 5 (ITGA5) gene circular RNA sponges microRNA-107 in colorectal carcinoma cells and tissues and regulates the expression of the forkhead Box J3 (FOXJ3) gene. Med Sci Monit 2020; 26: e920623.
[http://dx.doi.org/10.12659/MSM.920623] [PMID: 32305992]
[35]
Zhu H, Wang G, Zhu H, Xu A. ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors. BMC Cancer 2021; 21(1): 269.
[http://dx.doi.org/10.1186/s12885-021-07996-1] [PMID: 33711961]
[36]
Wang Y, Hou K, Jin Y, et al. Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways. J Transl Int Med 2021; 9(4): 249-63.
[http://dx.doi.org/10.2478/jtim-2021-0046] [PMID: 35136724]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy